Glybera

Type: Product
Name: Glybera
First reported Jul 16 2014 - Updated Jul 16 2014 - 1 reports

Some Elegant Biotech Platforms I Read About While Looking For The Next Regeneron

Summary Discovery and development platforms can efficiently multiply a drug pipeline. Regeneron leveraged its platforms to become a biotech paragon over the 5 years prior to 2014. Bluebird bio, Epizyme, Sangamo, and Benitec are among companies with ... [Published Seeking Alpha - Jul 16 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Tale of two biotech stars

In the wake of the financial crisis, one sector that has huge potential to boost and reboot Europe’s competitiveness – healthcare biotech – is facing an awkward combination of circumstances. National R&D budgets have been reduced, venture capital has ... [Published SCIENCE BUSINESS - Jul 10 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Global regenerative medicine market expected to record high growth during 2014-2024

(live-PR.com) - Regenerative medicine promises to one day provide cures for major diseases such as cancer, heart disease and diabetes, as well as a limitless supply of organs for transplantation. This exciting field covers therapies that restore the function ... [Published Live-PR.com - Jul 01 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

uniQure Secures Additional $10M Venture Loan from Hercules Capital

--Restructured Venture Debt Financing for Expansion and Advancement of Gene Therapy Pipeline--Amsterdam, the Netherlands, July 1, 2014 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the closing of an additional $10 million ... [Published Noodls - Jul 01 2014]
First reported Jun 26 2014 - Updated Jun 26 2014 - 1 reports

Personalized Medicine World Conference Honors Teva's Dr. Michael Hayden with 2014 Luminary Award

The Personalized Medicine World Conference (PMWC) reported that Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer of Teva Pharmaceuticals, is the recipient of the 2014 PMWC Luminary Award, for his contribution to the advancement ... [Published Individual.com - Jun 26 2014]
First reported Jun 24 2014 - Updated Jun 25 2014 - 1 reports

Bayer to create gene therapy with Dimension Therapeutics

Bayer has hit a union with U. S. biotech firm Dimension Therapeutics to create a gene treatment for the medicine of hemophilia A, checking restored enthusiasm toward a methodology to handle the reason for maladies at a cell level.Gene therapy includes ... [Published TopNews New Zealand - Jun 24 2014]
First reported Jun 23 2014 - Updated Jun 24 2014 - 2 reports

Bayer bets on gene therapy with Dimension deal

Gene therapy involves inserting corrective genes into malfunctioning cells to get them to work again without further use of drugs. Dimension has been looking into using viruses to carry the genes to the affected cells. Gene therapy has seen more than ... [Published NewsRT.co.uk - Jun 23 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

Personalized Medicine World Conference Luminary Award Granted to Dr. Michael Hayden

SAN JOSE, Calif. & HERTZELIA, Israel--(BUSINESS WIRE)-- The Personalized Medicine World Conference (PMWC) announced that Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer of Teva Pharmaceuticals, is the recipient of the 2014 PMWC ... [Published CNBC - Jun 23 2014]
First reported Jun 22 2014 - Updated Jun 22 2014 - 1 reports

New Gene Therapy Findings from University of Montreal Reported

(NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Data detailed on Biotechnology have been presented. According to news reporting out of Chicoutimi, Canada, by NewsRx editors, research stated, "Cellular immune responses to adeno-associated ... [Published NewsRX - Jun 22 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

Are neurologists ready to embrace gene therapy? - Physician Views

ScopeAs recently noted by Forbes, the biotech bull market of 2013 has helped to revive an approach to drug development that had become largely abandoned and pursued by only a few devoted believers. Between the beginning of last year and early April 2014, ... [Published MarketResearch.com - Jun 20 2014]
First reported Jun 18 2014 - Updated Jun 19 2014 - 4 reports

uniQure, Medison sign distribution agreement for Glybera

uniQure, a Netherlands-based provider of human gene therapy, has an exclusive distribution agreement with Medison Pharma, an Israeli healthcare marketing group. ... [Published PBR - News - Jun 19 2014]
First reported Jun 18 2014 - Updated Jun 19 2014 - 1 reports

New Gene Therapy Findings from University of Montreal Reported

By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Data detailed on Biotechnology have been presented. According to news reporting out of Chicoutimi, Canada , by NewsRx editors, research stated, "Cellular immune responses to adeno-associated ... [Published HispanicBusiness.com - Jun 18 2014]

Quotes

...istratively, big pharm is supporting financially, 4) bluebird has a powerful platform described in great detail in its 10K, 5) bluebird is investing "with a view towards supporting our …[gene therapy] candidates, if approved, at commercial scale." Commercial scale manufacturing is very unusual among small cap biotechs these days, but that is one of the capabilities that set Regeneron apart from...
...opportunities that will leverage our gene therapy platform and manufacturing expertise," commented Jörn Aldag, uniQure Chief Executive Officer. "Accessing the best third party programs in early development enables us to further expand our high quality pipeline, sustaining the Company's leadership position in gene therapy."
In his speech, Dr. Hayden referred to the largest challenge that is hindering the movement of personalized medicine into the clinic: "Currently the medical arena is focused on reimbursing and treating diseases. The entire concept should be changed, refocusing health care from treatment to prevention. Now that reading a patients’ genetic information is cheaper and easier than an MRI test we should approach this avenue more often. One area that has embraced personalized medicine is the field of cancer, where therapeutic direction depends on the genomes of the cancer and the patient. This is an area where TEVA has embedded a personalized approach into virtually all of its research projects, playing a significant role in the personalized medicine revolution."
Our news journalists obtained a quote from the research from the University of Montreal, "Five subjects with LPL deficiency (LPLD) were administered intramuscularly with a dose of 1x10(12) gc/kg alipogene tiparvovec. All subjects were treated with immune suppression starting shortly before administration of alipogene tiparvovec and maintained until 12 weeks after administration. Systemic antibody and T cell responses against AAV1 and LPLS447X, as well as local cellular immune responses in the injected muscle, were investigated in five LPLD subjects. Long-term transgene expression was demonstrated despite a transient systemic cellular response and a stable humoral immune response against the AAV1 capsid protein. Cellular infiltrates were found in four of the five subjects but were not associated with adverse clinical events or elevation of inflammation markers. Consistent herewith, CD8+ T cells in the infiltrates lacked cytotoxic potential. Furthermore, FoxP3+/CD4+ T cells were found in the infiltrates, suggesting that multiple mechanisms contribute to local tolerance. Systemic and local immune responses induced by intramuscular injection of alipogene tiparvovec did not appear to have an impact on safety and did not prevent LPL transgene expression."

More Content

All (25) | News (17) | Reports (0) | Blogs (5) | Audio/Video (0) | Fact Sheets (0) | Press Releases (3)
sort by: Date | Relevance
Some Elegant Biotech Platforms I Read About Whi... [Published Seeking Alpha - Jul 16 2014]
Tale of two biotech stars [Published SCIENCE BUSINESS - Jul 10 2014]
Global regenerative medicine market expected to... [Published Live-PR.com - Jul 01 2014]
uniQure Secures Additional $10M Venture Loan fr... [Published Noodls - Jul 01 2014]
Personalized Medicine World Conference Honors T... [Published Individual.com - Jun 26 2014]
Bayer to create gene therapy with Dimension The... [Published TopNews New Zealand - Jun 24 2014]
Bayer bets on gene therapy with Dimension deal [Published NewsRT.co.uk - Jun 23 2014]
Personalized Medicine World Conference Luminary... [Published CNBC - Jun 23 2014]
Bayer bets on gene therapy with Dimension deal [Published Sharenet - Jun 23 2014]
New Gene Therapy Findings from University of Mo... [Published NewsRX - Jun 22 2014]
Are neurologists ready to embrace gene therapy?... [Published MarketResearch.com - Jun 20 2014]
uniQure, Medison sign distribution agreement fo... [Published PBR - News - Jun 19 2014]
New Gene Therapy Findings from University of Mo... [Published HispanicBusiness.com - Jun 18 2014]
Medison to market uniQure's Glybera in Israel f... [Published News-Medical.Net - Jun 18 2014]
uniQure and Medison Sign Glybera Distribution A... [Published PR Newswire - Jun 18 2014]
uniQure and Medison Sign Glybera Distribution A... [Published PredictWallStreet - Jun 18 2014]
uniQure Announces Analysis of Six-Year Follow-u... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
uniQure and Medison Sign Glybera(R) Distributio... [Published GlobeNewswire: Acquisitions News - May 29 2014]
[tt] [GRG] NewAbs: Genome Editing to Cure AIDS [Published TranshumanTech - Mar 27 2014]
Gene Expression Analysis Market (Gene Profiling... [Published PRWeb - Mar 27 2014]
uniQure and Chiesi Announce Six Year Follow-up ... [Published GlobeNewswire: Acquisitions News - Mar 17 2014]
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
These Days, You Can't Spell Financings Of The F... [Published The IN VIVO Blog - Feb 07 2014]
Dutch gene therapy pioneer raises $82 mln in U.... [Published PE Hub Blog - Feb 06 2014]
Europe: Early Communications with Regulators is... [Published Pharmaceutical Executive - Jan 16 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
uniQure, Medison sign distribution agreement fo... [Published PBR - News - Jun 19 2014]
uniQure, a Netherlands-based provider of human gene therapy, has an exclusive distribution agreement with Medison Pharma, an Israeli healthcare marketing group. ...
[tt] [GRG] NewAbs: Genome Editing to Cure AIDS [Published TranshumanTech - Mar 27 2014]
To Members and Friends of the Los Angeles Gerontology Research Group:         Genome editing to cure disease... -- Steve Coles " Can Genome Editing Cure AIDS? " by Hank Greely, Center for Law and Biosciences at Stanford Law School and by ...
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
Forbion Capital Partners -backed uniQure , which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ . Jefferies and Leerink Partners acted as joint book-running managers and Piper ...
These Days, You Can't Spell Financings Of The F... [Published The IN VIVO Blog - Feb 07 2014]
It turns out a lot of the words that contain the letters "IPO" are biomedical words: Pluripotent. Liposomal. Adiposis. Gallipot . And it turns out a lot of biomedical companies have IPO in them, too. Since we last met 14 days ago , dear reader, ...
Dutch gene therapy pioneer raises $82 mln in U.... [Published PE Hub Blog - Feb 06 2014]
(Reuters) – A small Dutch company behind the Western world’s first approved gene therapy priced its shares above the expected range in a U.S. stock offering on Wednesday, showing the current investor appetite for biotechnology. Amsterdam-based uniQure ...
1

Press Releases

sort by: Date | Relevance
uniQure Announces Analysis of Six-Year Follow-u... [Published GlobeNewswire: Acquisitions News - Jun 03 2014]
uniQure and Medison Sign Glybera(R) Distributio... [Published GlobeNewswire: Acquisitions News - May 29 2014]
uniQure and Chiesi Announce Six Year Follow-up ... [Published GlobeNewswire: Acquisitions News - Mar 17 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.